ATE428769T1 - Methode und zusammensetzung zur herstellung von reifen dendritischen zellen - Google Patents

Methode und zusammensetzung zur herstellung von reifen dendritischen zellen

Info

Publication number
ATE428769T1
ATE428769T1 AT98120339T AT98120339T ATE428769T1 AT E428769 T1 ATE428769 T1 AT E428769T1 AT 98120339 T AT98120339 T AT 98120339T AT 98120339 T AT98120339 T AT 98120339T AT E428769 T1 ATE428769 T1 AT E428769T1
Authority
AT
Austria
Prior art keywords
dendritic cells
cells
cell
mature
mature dendritic
Prior art date
Application number
AT98120339T
Other languages
English (en)
Inventor
Ralph M Steinman
Nina Bhardwaj
Gerold Schuler
Original Assignee
Univ Rockefeller
Merix Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Merix Bioscience Inc filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE428769T1 publication Critical patent/ATE428769T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98120339T 1997-10-27 1998-10-27 Methode und zusammensetzung zur herstellung von reifen dendritischen zellen ATE428769T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6340297P 1997-10-27 1997-10-27

Publications (1)

Publication Number Publication Date
ATE428769T1 true ATE428769T1 (de) 2009-05-15

Family

ID=22048964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98120339T ATE428769T1 (de) 1997-10-27 1998-10-27 Methode und zusammensetzung zur herstellung von reifen dendritischen zellen

Country Status (4)

Country Link
US (1) US6274378B1 (de)
EP (2) EP2058389B1 (de)
AT (1) ATE428769T1 (de)
DE (1) DE69840739D1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
US20020085993A1 (en) * 1992-11-25 2002-07-04 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US20020132017A1 (en) * 1996-12-09 2002-09-19 Moore Jeffrey G. Composition and method for preserving progenitor cells
US6251665B1 (en) * 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6991794B1 (en) * 1997-06-24 2006-01-31 Imclone Systems Incorporated Progenitor cell preservation factors and methods for and products of their use
US6310195B1 (en) * 1997-06-24 2001-10-30 Imclone Systems Incorporated Nucleic acid encoding a lectin-derived progenitor cell preservation factor
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
EP1165144A2 (de) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Mit einem eigengen-wildtyp transduzierte dendritische zellen lösen starke antitumor immunantwort aus
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US6544506B2 (en) * 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
CA2408547A1 (en) * 2000-05-11 2001-11-15 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
WO2001090316A2 (en) * 2000-05-24 2001-11-29 Nexell Therapeutics, Inc. Human circulating dendritic cell compositions and methods
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
WO2002036748A2 (en) * 2000-11-03 2002-05-10 Nexell Therapeutics, Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
WO2002043651A2 (en) * 2000-11-30 2002-06-06 Yeda Research And Development Co. Ltd. Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
JP4394350B2 (ja) * 2001-01-09 2010-01-06 ベイラー リサーチ インスティテュート 対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ
KR100429140B1 (ko) * 2001-03-29 2004-04-29 (주)라이프코드 인간 조혈 모세포로부터 분화되는 림프구성 수상돌기 세포및 그의 생산 방법
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
JP2005505261A (ja) * 2001-07-05 2005-02-24 ファイロジックス・インコーポレーテッド 樹状細胞単離法
BRPI0212545B8 (pt) * 2001-09-06 2021-05-25 Northwest Biotherapeutics Inc método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
US20060292618A1 (en) * 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
WO2004024075A2 (en) * 2002-09-11 2004-03-25 Medical College Of Georgia Research Institute, Inc. Chemokine receptor antagonists as therapeutic agents
WO2004031361A2 (en) * 2002-10-03 2004-04-15 University Of Rochester Three-dimensional peripheral lymphoid organ cell cultures
US20050003534A1 (en) * 2002-11-07 2005-01-06 Eliezer Huberman Human stem cell materials and methods
US20040136973A1 (en) * 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
JP2006512060A (ja) * 2002-11-07 2006-04-13 ザ ユニヴァーシティ オヴ シカゴ ヒト幹細胞の材料および方法
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
AU2004204942A1 (en) * 2003-01-08 2004-07-29 Xencor, Inc Novel proteins with altered immunogenicity
JP2006517108A (ja) * 2003-02-10 2006-07-20 ノースウエスト バイオセラピューティクス，インコーポレイティド 培養されたｃｄ１４＋抗原提示細胞
US20060134067A1 (en) * 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
WO2004111075A2 (en) * 2003-03-05 2004-12-23 Dendreon Corporation Alternative reading frame polypeptides for treatment
US20050003533A1 (en) * 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
WO2004104185A1 (en) * 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
US20050260158A1 (en) * 2003-11-07 2005-11-24 Eliezer Huberman Human stem cell materials and methods
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7771999B2 (en) 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US7709256B2 (en) 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US7785883B2 (en) 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
ATE476497T1 (de) * 2004-08-19 2010-08-15 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
US20090208517A1 (en) * 2004-08-19 2009-08-20 Bernhard Moser Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006120439A2 (en) * 2005-05-10 2006-11-16 Avaris Ab Cellular vaccine and use thereof
WO2006124700A2 (en) * 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
CA2634123C (en) 2005-12-21 2015-11-24 Vaxdesign Corporation In vitro germinal centers
JP2009521228A (ja) * 2005-12-21 2009-06-04 ヴァックスデザイン コーポレーション 単球の樹状細胞への分化を促進する多孔質膜デバイス
US7709257B2 (en) * 2006-06-27 2010-05-04 Vax Design Corp. Models for vaccine assessment
CN104177464B (zh) 2006-08-18 2017-04-12 阿哥斯医疗公司 Cd83在联合治疗中的用途
CA2666789C (en) * 2006-10-18 2016-11-22 Yong Zhao Embryonic-like stem cells derived from adult human peripheral blood and methods of use
GB0622399D0 (en) * 2006-11-10 2006-12-20 Avaris Ab Novel compositions and uses thereof
US20080286315A1 (en) * 2007-01-31 2008-11-20 Penta Biotech, Inc. Methionine Enkephalin as an Adjuvant for Vaccine Immunizations
DE102007006736B4 (de) 2007-02-07 2012-01-12 Dagmar Briechle In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz
WO2009048661A1 (en) 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
WO2009070639A1 (en) 2007-11-28 2009-06-04 Irx Therapeutics, Inc. Method of increasing immunological effect
MX2011005915A (es) 2008-12-03 2011-08-17 Proyecto Biomedicina Cima Sl Uso de modulinas solubles en fenol para el desarrollo de vacunas.
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
CA2772076A1 (en) * 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US9211321B2 (en) * 2009-10-27 2015-12-15 Immunicum Ab Method for proliferation of antigen-specific T cells
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US9492529B2 (en) 2011-04-13 2016-11-15 Immunicum Ab Method for priming of T cells
CN103502439B (zh) * 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
KR101294528B1 (ko) 2011-09-23 2013-08-07 인제대학교 산학협력단 Ｅｂｖ 감염 ｂ 세포 유래의 복합 사이토카인을 포함하는 수지상세포 성숙 유도용 조성물
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
EP2812431B1 (de) 2012-02-09 2019-07-17 Baylor College Of Medicine Peptidmischungen zur erzeugung multiviraler ctl mit breiter spezifität
KR101568323B1 (ko) * 2014-01-08 2015-11-12 한국원자력의학원 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
US10350279B2 (en) 2014-06-23 2019-07-16 Jw Creagene Inc. Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
US10821134B2 (en) 2017-05-17 2020-11-03 Board Of Regents, The University Of Texas System BK virus specific T cells
WO2020102721A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als)
US10772914B1 (en) 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
US20230173065A1 (en) 2020-05-15 2023-06-08 Seoul National University R&Db Foundation Composition for enhancing immune response by using activation function of dendritic cells of stromal vascular fractions isolated from adipose tissues
CN121335708A (zh) 2023-05-01 2026-01-13 耶鲁大学 用于疫苗接种的抗原特异性生理性树突状细胞
JP2026516460A (ja) 2023-05-01 2026-05-25 エール・ユニバーシティ 療法用の抗原特異的生理的樹状細胞

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0628419B2 (ja) 1984-06-21 1994-04-13 ソニー株式会社 画像調整装置
US4861589A (en) 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US20030072751A1 (en) 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
IL103928A0 (en) 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
EP0563485A1 (de) 1992-03-30 1993-10-06 Schering-Plough In-vitro-Erzeugung von menschlichen dendritischen Zellen
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
WO1994002156A1 (en) 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
WO1995015340A1 (en) 1993-12-03 1995-06-08 The Board Of Trustees Of Leland Stanford Junior University Monoclonal antibodies to antigens expressed by human dendritic cells
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
DK0765386T3 (en) 1994-06-14 2015-01-26 Univ Leland Stanford Junior Methods for T cell activation in vivo with antigen-incubated dendritic cells
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US8600483B2 (en) 2006-03-20 2013-12-03 California Institute Of Technology Mobile in vivo infra red data collection and diagnoses comparison system

Also Published As

Publication number Publication date
EP2058389A1 (de) 2009-05-13
EP0922758A3 (de) 2001-12-19
EP0922758A2 (de) 1999-06-16
EP0922758B1 (de) 2009-04-15
US6274378B1 (en) 2001-08-14
DE69840739D1 (de) 2009-05-28
EP2058389B1 (de) 2016-05-18

Similar Documents

Publication Publication Date Title
DE69840739D1 (de) Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
ATE268812T1 (de) Methode und zusammensetzungen zum erlangen reifer dendritischer zellen
DE69431135D1 (de) Methode zur Herstellung von Taxan-Typ Diterpen und Methode zur Gewinnung von Kulturzellen die Taxan-Typ Diterpen in hohen Ausbeuten herstellen
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
EP0918848A4 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
DE69841146D1 (de) Zellulares vesikel 'exosome', seine Herstellung und Verwendung zur Stimulierung eines Immunantworts
DE3855921D1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
DE3885983D1 (de) Verfahren zur Herstellung des rekombinanten menschlichen Faktors VIII:C.
BR9305952A (pt) Produto de controle de hematologia processo para utilizar o mesmo e processo para fabricação de análogos de leucócito
MY113048A (en) Compositions and methods for stimulating megakaryocyte growth and differentiation
DE68929134D1 (de) Endothelin-DNA und Verwendung davon
DE69229944D1 (de) Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
DE69131069D1 (de) Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
ATE71144T1 (de) Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung.
DE69109886D1 (de) Verfahren zur Herstellung von humanem Faktor VIII und dessen Analogen.
ATE210695T1 (de) Verfahren zur herstellung von poly(diorganosiloxanen), mischungen, enthaltend diese poly(diorganosiloxane) und deren verwendung
DE69012377D1 (de) Polypeptid und dessen Herstellung.
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
ATE184646T1 (de) Kallus-zellen-induktion und herstellung von taxanen
ATE220714T1 (de) Verfahren zur herstellung von proteinen
NO180636C (no) Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1
DE3768747D1 (de) Aminosaeureester von cycloaliphatischen alkoholen, verfahren zur herstellung und verwendung als arzneimittel.
ATE87973T1 (de) Expressionsvektoren fuer die produktion von humanem gm-csf in saengerzellen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties